In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Justin Hotard is appointed Nokia’s new CEO, just months after former Intel boss Pat Gelsinger retired. Trump's "America First ...

An image that is spreading widely online claims that Moderna had created its COVID-19 vaccine two years before the pandemic ...

A recent article published by specialists from BCG (Boston Consulting Group) and INSEAD discusses how AI 'coworkers' are ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

It’s time for a new era of public health—where vaccines are seen as both a scientific triumph and a shared commitment to well-being of all.

The S&P 500 fell 0.5% on Wednesday, Jan. 29, as the Federal Reserve held interest rates steady in a move widely expected by the financial markets.